

# Pietro Lampertico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886685/publications.pdf>

Version: 2024-02-01

308  
papers

17,924  
citations

20817

60  
h-index

15732

125  
g-index

313  
all docs

313  
docs citations

313  
times ranked

13445  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute kidney injury and chronic kidney disease after liver transplant: A retrospective observational study. <i>Nefrologia</i> , 2022, 42, 27-35.	0.4	2
2	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	3.7	48
3	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
4	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
5	Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 464-469.	3.7	48
6	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 350-359.	3.7	11
7	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 867-877.	4.3	6
8	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 921-943.	3.7	14
9	Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. <i>Frontiers in Medicine</i> , 2022, 9, 834354.	2.6	22
10	Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1044-1045.	3.7	1
11	Implementation of HCV screening in the 1969–1989 birth cohort undergoing COVID-19 vaccination. <i>Liver International</i> , 2022, 42, 1012-1016.	3.9	13
12	Reproducibility and diagnostic accuracy of pocket-sized ultrasound devices in ruling out compensated cirrhosis of mixed etiology. <i>European Radiology</i> , 2022, 32, 4609-4615.	4.5	8
13	Is it time to refine HCC surveillance strategies in HCV cured patients?. <i>Hepatology</i> , 2022, 76, 9-11.	7.3	2
14	Editorial: the role for PIVKA measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 124-125.	3.7	0
15	An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 109.	2.4	0
16	Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2022, 54, 1520-1526.	0.9	12
17	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. <i>Advances in Therapy</i> , 2022, 39, 3146-3158.	2.9	6
18	Bulevirtide with or without pegIFN± for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. <i>Journal of Hepatology</i> , 2022, 77, 1422-1430.	3.7	54

#	ARTICLE	IF	CITATIONS
19	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. <i>Journal of Hepatology</i> , 2022, 77, 1670-1689.	3.7	26
20	Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19. <i>Gut</i> , 2021, 70, 1798-1799.	12.1	1
21	Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B" <i>Journal of Hepatology</i> , 2021, 74, 246-247.	3.7	1
22	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.9	6
23	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 464-474.	2.0	4
24	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	3.7	26
25	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	3.7	33
26	Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. <i>Antiviral Research</i> , 2021, 185, 104992.	4.1	19
27	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	2.0	3
28	Combined approach for embolization of otherwise unmanageable gastric varices. <i>Annals of Gastroenterology</i> , 2021, 34, 510-515.	0.6	0
29	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal $\beta$ -Blocker Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1342-1344.	0.4	12
30	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3a-infected patients within the Italian network VIRONET. <i>Liver International</i> , 2021, 41, 1802-1814.	3.9	12
31	Dual proteotoxic stress accelerates liver injury via activation of $p62^{\text{Nrf2}}$ . <i>Journal of Pathology</i> , 2021, 254, 80-91.	4.5	1
32	The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). <i>PLoS ONE</i> , 2021, 16, e0249614.	2.5	15
33	Cost analysis of a long-term randomized controlled study in biliary duct-to-duct anastomotic stricture after liver transplantation. <i>Transplant International</i> , 2021, 34, 825-834.	1.6	7
34	Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?. <i>Journal of Hepatology</i> , 2021, 74, 1011-1014.	3.7	3
35	Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. <i>Advances in Therapy</i> , 2021, 38, 3409-3426.	2.9	7
36	Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 713-739.	3.7	10

#	ARTICLE	IF	CITATIONS
37	Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis B Infection Treated with Glecaprevir/Pibrentasvir. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2203-2222.	4.0	11
38	Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. <i>Gut</i> , 2021, 70, 1782-1794.	12.1	125
39	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
40	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1443-1451.	2.0	1
41	The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. <i>Viral Immunology</i> , 2021, 34, 542-551.	1.3	2
42	The times they are a-changing – A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021, 75, 474-480.	3.7	46
43	Reply to: Correspondence on “the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.”. <i>Journal of Hepatology</i> , 2021, 75, 1499-1501.	3.7	0
44	IDDF2021-ABS-0080 – 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
45	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
46	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. <i>Hepatology Communications</i> , 2021, 5, 1824-1832.	4.3	37
47	Novel Therapies That May Cure Chronic Hepatitis B Virus. <i>Clinics in Liver Disease</i> , 2021, 25, 875-899.	2.1	5
48	Clinical Evaluation of Plasma Separation Cards as a Tool to Collect, Store, and Test Blood Samples for Hepatitis B and C Serological Markers. <i>Clinical Chemistry</i> , 2021, 68, 214-217.	3.2	2
49	Incremental value of HBcrAg to classify 1582 HBsAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 733-744.	3.7	18
50	Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019. <i>Liver International</i> , 2021, 41, 3028-3032.	3.9	5
51	COVID-19 Vaccine Acceptance among Liver Transplant Recipients. <i>Vaccines</i> , 2021, 9, 1314.	4.4	17
52	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	3.7	13
53	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir – new clues from Europe. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 657-658.	3.7	2
54	Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 34-44.	3.7	57

#	ARTICLE	IF	CITATIONS
55	Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues. <i>Gastroenterology</i> , 2020, 158, 42-44.	1.3	9
56	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
57	How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?. <i>Hepatology Communications</i> , 2020, 4, 5-7.	4.3	6
58	Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. <i>Liver International</i> , 2020, 40, 484-495.	3.9	42
59	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	3.7	208
60	Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 568-574.	1.0	40
61	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020, 52, 190-198.	0.9	12
62	High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. <i>Liver International</i> , 2020, 40, 1062-1068.	3.9	13
63	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. <i>Cell Reports Medicine</i> , 2020, 1, 100060.	6.5	18
64	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
65	Hepatic Fat Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020, 72, 1912-1923.	7.3	48
66	Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e128-e129.	1.9	1
67	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , 2020, 52, 1164-1169.	0.9	7
68	Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19". <i>Journal of Hepatology</i> , 2020, 73, 1570-1571.	3.7	10
69	A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results. <i>Journal of Hepatology</i> , 2020, 73, S67-S68.	3.7	4
70	Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data. <i>Journal of Hepatology</i> , 2020, 73, S129-S130.	3.7	33
71	Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. <i>Advances in Therapy</i> , 2020, 37, 4033-4042.	2.9	18
72	Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa" the case of Uganda. <i>Journal of Hepatology</i> , 2020, 73, 1273-1274.	3.7	1

#	ARTICLE	IF	CITATIONS
73	Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study. <i>Journal of Hepatology</i> , 2020, 73, S868-S869.	3.7	1
74	Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials. <i>Journal of Hepatology</i> , 2020, 73, S883-S885.	3.7	3
75	Management of hepatocellular carcinoma in the time of COVID-19. <i>Annals of Oncology</i> , 2020, 31, 1084-1085.	1.2	33
76	Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. <i>Frontiers in Oncology</i> , 2020, 10, 381.	2.8	7
77	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	3.7	69
78	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	3.7	279
79	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 500-512.	3.7	9
80	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 1112-1121.	3.7	62
81	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	8.1	85
82	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	3.7	75
83	Comparison of three therapeutic regimens for genotype 3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020, 40, 769-777.	3.9	15
84	Epidemiology and surveillance for hepatocellular carcinoma: New trends. <i>Journal of Hepatology</i> , 2020, 72, 250-261.	3.7	633
85	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	3.7	38
86	Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy". <i>Journal of Hepatology</i> , 2020, 73, 223-224.	3.7	0
87	Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2131-2133.e1.	4.4	38
88	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	3.9	44
89	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	2.5	2
90	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66

#	ARTICLE	IF	CITATIONS
91	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight, 2020, 5, .	5.0	2
92	Addition peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B antigen-negative chronic hepatitis B genotype D. Journal of Viral Hepatitis, 2019, 26, 118-125.	2.0	21
93	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Journal of Hepatology, 2019, 71, 1106-1115.	3.7	69
94	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. Journal of Hepatology, 2019, 70, e234-e235.	3.7	1
95	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	3.9	8
96	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. Liver International, 2019, 39, 1964-1974.	3.9	11
97	Excellent safety and effectiveness of high-dose myrccludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. Journal of Hepatology, 2019, 71, 834-839.	3.7	53
98	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	4.7	60
99	Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Liver Cancer Risk Reduction: Better Nucleotides than Nucleosides?. Gastroenterology, 2019, 157, 1682-1684.	1.3	3
100	Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review. Transplantation Proceedings, 2019, 51, 2998-3000.	0.6	2
101	THU-151-Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies. Journal of Hepatology, 2019, 70, e228.	3.7	2
102	Assessing spleen stiffness by point shear-wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. GastroHep, 2019, 1, 205-213.	0.6	3
103	JNJ4178 (AL335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology, 2019, 69, 2349-2363.	7.3	6
104	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. Digestive and Liver Disease, 2019, 51, 1135-1140.	0.9	18
105	Hepatitis D " how is the fight against this foe going?. Expert Review of Clinical Pharmacology, 2019, 12, 169-171.	3.1	3
106	TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. Journal of Viral Hepatitis, 2019, 26, 1233-1236.	2.0	10
107	Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB " Is one NUC better than the other?. Journal of Hepatology, 2019, 71, 453-455.	3.7	16
108	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341

#	ARTICLE	IF	CITATIONS
109	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. <i>Annals of Hepatology</i> , 2019, 18, 318-324.	1.5	4
110	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9
111	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
112	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1040-1049.	2.0	3
113	Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 993-995.	5.2	1
114	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- $\beta$ 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	3.3	7
115	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
116	IDDF2019-ABS-0169...A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
117	Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study. <i>Transplant International</i> , 2019, 32, 493-501.	1.6	9
118	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
119	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
120	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.9	47
121	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, 379-387.	3.7	109
122	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	4.4	79
123	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 419-424.	0.9	9
124	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	3.9	9
125	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 615-625.	3.7	204
126	Endo-therapies for biliary duct-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey. <i>Liver International</i> , 2019, 39, 1355-1362.	3.9	18



#	ARTICLE	IF	CITATIONS
127	High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1089-1090.	1.9	6
128	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2018, 154, 1764-1777.e7.	1.3	123
129	Suppressive effects of tenofovir disoproxil fumarate, an antiretroviral prodrug, on mineralization and type II and type III sodium-dependent phosphate transporters expression in primary human osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4855-4866.	2.6	13
130	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <sc>IFN</sc> and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	3.9	22
131	Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 397-400.	7.3	36
132	Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 153-161.	4.4	15
133	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
134	Treatment of hepatitis B: Is there still a role for interferon?. <i>Liver International</i> , 2018, 38, 79-83.	3.9	40
135	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. <i>Digestive and Liver Disease</i> , 2018, 50, 944-953.	0.9	33
136	High efficacy of direct-acting antiviral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712.	3.7	26
137	12 weeks ombitasvir/paritaprevir-ritonavir+ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. <i>Digestive and Liver Disease</i> , 2018, 50, 703-706.	0.9	0
138	<i>rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in <sc>IFN</sc>-treated HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2018, 38, 417-423.	3.9	8
139	Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. <i>Journal of Hepatology</i> , 2018, 68, 195-198.	3.7	18
140	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. <i>Current Hepatology Reports</i> , 2018, 17, 502-510.	0.9	1
141	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	3.8	54
142	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	3.9	25
143	An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings. <i>Antiviral Therapy</i> , 2018, 23, 655-663.	1.0	6
144	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 431-439.	3.7	7

#	ARTICLE	IF	CITATIONS
145	A <sc>STAT</sc>4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.	3.7	17
146	A baseline tool for predicting response to peginterferon alfa-2a in <sc>HB</sc>eAg<sup>+</sup> positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 547-555.	3.7	27
147	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
148	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.6	4
149	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (<sc>NUC</sc>s). <i>Liver International</i> , 2017, 37, 45-51.	3.9	65
150	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	30.7	251
151	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 370-398.	3.7	3,803
152	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
153	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909.	3.7	125
154	Editorial: good news to patients with thalassaemia – HCV clearance made easy with direct-acting antivirals. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 628-629.	3.7	2
155	Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature. <i>Hemoglobin</i> , 2017, 41, 131-133.	0.8	5
156	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , 2017, 102, e423-e426.	3.5	7
157	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.	2.5	23
158	Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 917-926.	3.1	31
159	A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B. <i>Journal of Hepatology</i> , 2016, 64, S599-S600.	3.7	3
160	Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 653-661.	3.7	29
161	Letter: long-term safety of nucleoside and nucleotide analogues in <sc>HBV</sc>-monoinfected patients – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 538-538.	3.7	1
162	Review article: long-term safety of nucleoside and nucleotide analogues in <sc>HBV</sc>-monoinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 16-34.	3.7	92

#	ARTICLE	IF	CITATIONS
163	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016, 65, 1998-2006.	12.1	50
164	The prognosis and management of inactive HBV carriers. <i>Liver International</i> , 2016, 36, 100-104.	3.9	60
165	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc“positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	2.0	49
166	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	3.7	358
167	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016, 64, 773-780.	3.7	223
168	Nucleos(t)ide Analogue Based Therapy and Management of Patients. <i>Molecular and Translational Medicine</i> , 2016, , 339-359.	0.4	0
169	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	3.9	2
170	Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?. <i>Gut</i> , 2015, 64, 526-528.	12.1	17
171	Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?. <i>Current Hepatology Reports</i> , 2015, 14, 279-283.	0.9	0
172	Optimal therapy of chronic hepatitis B: how do I treat my HBeAg“negative patients?. <i>Liver International</i> , 2015, 35, 107-113.	3.9	21
173	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	3.7	398
174	The royal wedding in chronic hepatitis B: The haves and the have“nots for the combination of pegylated interferon and nucleos(t)ide therapy. <i>Hepatology</i> , 2015, 61, 1459-1461.	7.3	18
175	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	3.7	138
176	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
177	LP25 : Add-on peginterferon ALFA-2A significantly reduces hbsag levels in hbeag-negative, genotype d chronic hepatitis b patients fully suppressed on nucleot(s)ide analogue treatment: The hermes study. <i>Journal of Hepatology</i> , 2015, 62, S276.	3.7	7
178	P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC). <i>Journal of Hepatology</i> , 2015, 62, S559-S560.	3.7	4
179	P0647 : Proactive dose adjustments are necessary in many ADV-experienced patients treated with TDF monotherapy for 5 years: A prospective cohort study in 320 patients. <i>Journal of Hepatology</i> , 2015, 62, S562-S563.	3.7	1
180	P0655 : Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin's B cell lymphoma. <i>Journal of Hepatology</i> , 2015, 62, S566.	3.7	2

#	ARTICLE	IF	CITATIONS
181	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , 2015, 63, 1118-1125.	3.7	74
182	Optimal management of hepatitis B virus infection – EASL Special Conference. <i>Journal of Hepatology</i> , 2015, 63, 1238-1253.	3.7	91
183	Natural killer cell phenotype modulation and natural killer/Tâ€œcell interplay in nucleos(t)ide analogueâ€œtreated hepatitis e antigenâ€œnegative patients with chronic hepatitis B. <i>Hepatology</i> , 2015, 62, 1697-1709.	7.3	73
184	The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7213-7224.	4.1	19
185	Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. <i>Gut</i> , 2014, 63, 869-870.	12.1	6
186	Letter: does the <i><sc>IFNL</sc>4</i> gene discovery really provide a causal role for the <i><sc>IL</sc>28B</i> haplotype blocks?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 548-549.	3.7	1
187	Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. <i>Journal of Clinical Virology</i> , 2014, 61, 600-603.	3.1	62
188	Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis <sc>B</sc> infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 430-438.	2.0	37
189	<sc>HB</sc>eAgâ€œnegative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?. <i>Liver International</i> , 2014, 34, 120-126.	3.9	15
190	The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 21.	5.3	4
191	Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1251-1252.	3.7	0
192	Systematic review with metaâ€œanalysis: do interferon lambda 3 polymorphisms predict the outcome of interferonâ€œtherapy in hepatitis B infection?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 569-578.	3.7	40
193	P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF). <i>Journal of Hepatology</i> , 2014, 60, S435.	3.7	10
194	P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGS. <i>Journal of Hepatology</i> , 2014, 60, S429-S430.	3.7	2
195	Low risk of hepatitis B virus reactivation in HBsAg negative, anti-HBc positive carriers undergoing rituximab for rheumatoid arthritis. <i>Digestive and Liver Disease</i> , 2014, 46, e23.	0.9	2
196	Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1019-1031.	3.1	26
197	Non-invasive assessment of liver fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 14568.	3.3	43
198	Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. <i>Journal of Virological Methods</i> , 2013, 187, 271-273.	2.1	3

#	ARTICLE	IF	CITATIONS
199	Nucleos(t)ide Analogs-Based Chemoprevention of Liver Cancer in Hepatitis B Patients: Effective, Yet in Search of Optimization. <i>Gastroenterology</i> , 2013, 145, 1155-1156.	1.3	1
200	Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 553-554.	3.7	1
201	Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. <i>Journal of Hepatology</i> , 2013, 58, 287-296.	3.7	99
202	Results of Treatment of Chronic Hepatitis B with Pegylated Interferon. <i>Clinics in Liver Disease</i> , 2013, 17, 425-443.	2.1	6
203	755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS. <i>Journal of Hepatology</i> , 2013, 58, S306-S307.	3.7	19
204	Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?. <i>Liver International</i> , 2013, 33, 157-163.	3.9	17
205	PegIFN- $\alpha$ 2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.	4.4	15
206	IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. <i>Hepatology</i> , 2013, 57, 890-896.	7.3	153
207	Randomised study comparing 48 and 96 weeks peginterferon $\alpha$ -2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298.	12.1	105
208	The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. <i>BMJ Open</i> , 2013, 3, e001309.	1.9	3
209	Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?. <i>Clinical Liver Disease</i> , 2013, 2, 21-23.	2.1	4
210	Reply:. <i>Hepatology</i> , 2013, 57, 1283-1284.	7.3	6
211	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. <i>Hepatology</i> , 2013, 58, 1245-1252.	7.3	69
212	Discontinuation of nucleoside analogues in hepatitis B virus infection. <i>Gastroenterology and Hepatology</i> , 2013, 9, 656-8.	0.1	1
213	New perspectives in the therapy of chronic hepatitis B. <i>Gut</i> , 2012, 61, i18-i24.	12.1	51
214	Clinical implications of HBsAg quantification in patients with chronic hepatitis B. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 81.	1.1	24
215	523 ADD-ON PEG-IFN IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY NUCLEOS(T)IDE ANALOGS. <i>Journal of Hepatology</i> , 2012, 56, S207.	3.7	5
216	524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S207-S208.	3.7	6

#	ARTICLE	IF	CITATIONS
217	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 193-207.	3.1	85
218	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	3.7	114
219	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012, 56, 1006-1011.	3.7	155
220	Peginterferon- $\alpha$ 2 does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	3.7	75
221	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	3.7	29
222	IL-10 Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. <i>Journal of Immunology</i> , 2012, 189, 3925-3935.	0.8	310
223	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2012, 143, 963-973.e9.	1.3	308
224	Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. <i>Journal of Hepatology</i> , 2012, 57, 1326-1335.	3.7	27
225	Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. <i>Current Hepatitis Reports</i> , 2012, 11, 90-94.	0.3	5
226	First-line treatment of chronic hepatitis B with entecavir or tenofovir in "real-life" settings: from clinical trials to clinical practice. <i>Journal of Viral Hepatitis</i> , 2012, 19, 377-386.	2.0	109
227	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 455-464.	1.5	4
228	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.9	29
229	Antiviral drugs for HBV liver disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 285-300.	3.1	21
230	Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. <i>Journal of Hepatology</i> , 2011, 54, 621-628.	3.7	110
231	730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFN $\alpha$ -2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS. <i>Journal of Hepatology</i> , 2011, 54, S293.	3.7	3
232	731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2011, 54, S293-S294.	3.7	4
233	Hbv-Related Liver Disease in Renal Insufficiency: Successful Antiviral Therapy with Entecavir. <i>International Journal of Artificial Organs</i> , 2011, 34, 1031-1035.	1.4	5
234	The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/Ribavirin Therapy. <i>Antiviral Therapy</i> , 2011, 16, 677-684.	1.0	48

#	ARTICLE	IF	CITATIONS
235	P23 Comparison of enhanced liver fibrosis test and transient elastography for the non-invasive assessment of liver fibrosis in chronic hepatitis B. <i>Gut</i> , 2011, 60, A10-A11.	12.1	0
236	Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 353-362.	3.7	66
237	Application of transient elastography in chronic hepatitis B: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 818-819.	3.7	0
238	Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. <i>Liver International</i> , 2011, 31, 90-94.	3.9	9
239	Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 125-131.	2.4	84
240	Drug safety evaluation of adefovir in HBV infection. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 809-818.	2.4	33
241	Current Management of HBV Antiviral Drug Resistance. <i>Current Hepatitis Reports</i> , 2011, 10, 120-127.	0.3	0
242	Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2037-2041.	0.7	14
243	Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 180-184.	1.6	47
244	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. <i>Journal of Hepatology</i> , 2010, 53, 348-356.	3.7	397
245	14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION. <i>Journal of Hepatology</i> , 2010, 52, S7.	3.7	7
246	98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2010, 52, S45.	3.7	16
247	HBV and HCV Therapy. <i>Viruses</i> , 2009, 1, 484-509.	3.3	7
248	HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. <i>Liver International</i> , 2009, 29, 130-132.	3.9	6
249	Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. <i>Journal of Hepatology</i> , 2009, 50, 644-647.	3.7	22
250	EFFECTIVENESS OF ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE. <i>Digestive and Liver Disease</i> , 2009, 41, S50.	0.9	2
251	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. <i>Antiviral Therapy</i> , 2009, 14, 789-796.	1.0	15
252	Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. <i>Journal of Viral Hepatitis</i> , 2008, 15, 922-924.	2.0	2

#	ARTICLE	IF	CITATIONS
253	The use of molecular assays in the management of viral hepatitis. <i>Digestive and Liver Disease</i> , 2008, 40, 395-404.	0.9	16
254	Entecavir for lamivudine-naïve patients with chronic hepatitis B. <i>Digestive and Liver Disease Supplements</i> , 2008, 2, 7-10.	0.2	0
255	389 LOW RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A 3-YEAR FOLLOW-UP STUDY IN 78 PATIENTS WITH CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2008, 48, S151.	3.7	1
256	696 ADD ON ADEFOVIR PREVENTS THE EMERGENCE OF ADV RESISTANCE IN LAMIVUDINE-RESISTANT PATIENTS: A 4-YEAR STUDY. <i>Journal of Hepatology</i> , 2008, 48, S259.	3.7	7
257	Prophylaxis and treatment of Hepatitis B in immunocompromised patients. <i>Hepatitis B Annual</i> , 2008, 5, 23.	0.0	1
258	Management of lamivudine resistance: An overview. <i>Hepatitis B Annual</i> , 2008, 5, 66.	0.0	0
259	Acute hepatitis following assumption of a herbal remedy. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 364-365.	1.6	6
260	Hepatitis B Virus Infection in the Dialysis Population: Current Perspectives. <i>International Journal of Artificial Organs</i> , 2008, 31, 386-394.	1.4	17
261	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. <i>Journal of Experimental Medicine</i> , 2007, 204, 667-680.	8.5	385
262	[496] SIX YEARS OF ON DEMAND LAM±ADV COMBINATION THERAPY SIGNIFICANTLY REDUCES THE DEVELOPMENT AND PROGRESSION OF ESOPHAGEAL VARICES IN PATIENTS WITH HBeAg-NEGATIVE CIRRHOSIS. <i>Journal of Hepatology</i> , 2007, 46, S189.	3.7	4
263	[502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2007, 46, S191.	3.7	20
264	Natural History and Clinical Impact of Cryoglobulins in Chronic Hepatitis C: 10-Year Prospective Study of 343 Patients. <i>Gastroenterology</i> , 2007, 133, 835-842.	1.3	34
265	Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients. <i>Gastroenterology</i> , 2007, 133, 1445-1451.	1.3	290
266	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.9	197
267	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	2.4	239
268	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 133-139.	2.0	47
269	85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 44, S38.	3.7	8
270	Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. <i>Journal of Clinical Virology</i> , 2006, 35, 467-469.	3.1	38



#	ARTICLE	IF	CITATIONS
271	Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2006, 45, 457-460.	3.7	10
272	Natural History of Hepatitis B and C in Renal Allograft Recipients. <i>Transplantation</i> , 2005, 79, 1132-1136.	1.0	112
273	Review article: hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 623-632.	3.7	21
274	Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. <i>Hepatology</i> , 2005, 42, 1414-1419.	7.3	270
275	Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. <i>Liver Transplantation</i> , 2005, 11, 532-538.	2.4	78
276	Natural History of Hepatitis C Virus Infection in Adult Renal Graft Recipients. <i>Transplantation Proceedings</i> , 2005, 37, 940-941.	0.6	17
277	Long-Term Lamivudine Monotherapy in Renal-Transplant Recipients with Hepatitis-B-Related Cirrhosis. <i>Antiviral Therapy</i> , 2005, 10, 709-713.	1.0	15
278	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.9	83
279	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004, 40, 883-891.	7.3	201
280	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004, 40, 883-891.	7.3	237
281	Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. <i>Hepatology</i> , 2003, 37, 756-763.	7.3	189
282	The clinical and pathogenetic significance of estrogen receptor $\alpha$ expression in chronic liver diseases and liver carcinoma. <i>Cancer</i> , 2003, 98, 529-534.	4.1	54
283	Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. <i>Clinical Transplantation</i> , 2003, 17, 554-559.	1.6	34
284	A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2003, 10, 423-426.	2.0	6
285	High prevalence, low pathogenicity in hepatitis G virus in kidney transplant recipients. <i>Digestive and Liver Disease</i> , 2001, 33, 477-479.	0.9	18
286	High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. <i>Hepatology</i> , 2001, 34, 523-528.	7.3	106
287	Worse outcome in younger adult renal graft recipients with HCV infection. An 8-year prospective study. <i>Transplant International</i> , 2000, 13, S90-S91.	1.6	0
288	Clinical evaluation and applications of the Amplicor HBV Monitor $\text{\textcircled{C}}$ test, a quantitative HBV DNA PCR assay. <i>Journal of Virological Methods</i> , 1998, 74, 155-165.	2.1	86

#	ARTICLE	IF	CITATIONS
289	Long-term evolution of anti-HCV-positive renal transplant recipients. <i>Transplantation Proceedings</i> , 1998, 30, 2076-2078.	0.6	16
290	A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. <i>Hepatology</i> , 1997, 26, 1621-1625.	7.3	172
291	Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. <i>American Journal of Kidney Diseases</i> , 1996, 28, 437-440.	1.9	29
292	Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. <i>Journal of Viral Hepatitis</i> , 1995, 2, 251-256.	2.0	17
293	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.	7.3	110
294	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.	7.3	4
295	A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.	7.3	15
296	Detection of the hepatitis B virus major pre-core mutation by the amplification refractory mutation system technique. <i>Research in Virology</i> , 1993, 144, 307-309.	0.7	6
297	Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. <i>Research in Virology</i> , 1993, 144, 303-306.	0.7	6
298	Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion.. <i>Gut</i> , 1993, 34, S141-S141.	12.1	11
299	The Effect of Cytological Screening on Cervical Neoplasia in the Italian Province of Varese. <i>Tumori</i> , 1992, 78, 295-299.	1.1	2
300	Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics. <i>Hepatology</i> , 1991, 13, 422-426.	7.3	27
301	Detection of hepatitis C virus sequences in liver tissue by the polymerase chain reaction. <i>Laboratory Investigation</i> , 1991, 65, 408-11.	3.7	8
302	Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics. <i>Hepatology</i> , 1991, 13, 422-6.	7.3	29
303	Utility of Ascitic Fluid Analysis in Patients with Malignancy-Related Ascites. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 251-256.	1.5	20
304	Detection of hepatitis B virus DNA in formalin-fixed, paraffin-embedded liver tissue by the polymerase chain reaction. <i>American Journal of Pathology</i> , 1990, 137, 253-8.	3.8	32
305	Utility of ascitic fluid analysis in patients with malignancy-related ascites. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 251-6.	1.5	4
306	Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. <i>Hepatology</i> , 1989, 9, 693-697.	7.3	62

#	ARTICLE	IF	CITATIONS
307	Serum procollagen type III peptide levels in patients with acute viral hepatitis. Research in Clinic and Laboratory, 1988, 18, 37-44.	0.3	5
308	Natural History of Chronic Hepatitis B and Hepatocellular Carcinoma. , 0, , 263-268.		1